

Richard Kaplan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7930566/publications.pdf>

Version: 2024-02-01

41
papers

2,217
citations

236833

25
h-index

289141

40
g-index

41
all docs

41
docs citations

41
times ranked

2933
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study. <i>Antiviral Therapy</i> , 2022, 27, 135965352210774.	0.6	4
2	Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective. <i>Aids</i> , 2021, 35, S153-S163.	1.0	1
3	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 253-264.	4.6	114
4	HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. <i>PLoS ONE</i> , 2019, 14, e0210937.	1.1	28
5	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 535-544.	2.9	122
6	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
7	Resistance to first-line ART and a role for dolutegravir. <i>Lancet HIV</i> , the, 2018, 5, e112-e113.	2.1	3
8	HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. <i>BMC Infectious Diseases</i> , 2018, 18, 356.	1.3	22
9	Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial. <i>Antiviral Therapy</i> , 2017, 22, 215-223.	0.6	26
10	Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. <i>Aids</i> , 2017, 31, 953-963.	1.0	72
11	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , the, 2017, 4, e486-e494.	2.1	31
12	Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002434.	3.9	16
13	The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. <i>Bulletin of the World Health Organization</i> , 2017, 95, 554-563.	1.5	27
14	The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 536.	1.3	29
15	Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 748-749.	4.6	0
16	Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. <i>Tropical Medicine and International Health</i> , 2015, 20, 518-526.	1.0	36
17	Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. <i>Tropical Medicine and International Health</i> , 2014, 19, 1029-1039.	1.0	26
18	Impact of ART on TB Case Fatality Stratified by CD4 Count for HIV-Positive TB Patients in Cape Town, South Africa (2009-2011). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 487-494.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV. <i>Tropical Medicine and International Health</i> , 2013, 18, 1400-1405.	1.0	9
20	Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa. <i>PLoS ONE</i> , 2013, 8, e55824.	1.1	52
21	The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa. <i>PLoS ONE</i> , 2013, 8, e54435.	1.1	2
22	Increasing Transfers-Out from an Antiretroviral Treatment Service in South Africa: Patient Characteristics and Rates of Virological Non-Suppression. <i>PLoS ONE</i> , 2013, 8, e57907.	1.1	24
23	Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir. <i>PLoS ONE</i> , 2013, 8, e63596.	1.1	34
24	Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services. <i>South African Medical Journal</i> , 2012, 102, 936.	0.2	11
25	Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	0.9	19
26	Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. <i>BMC Infectious Diseases</i> , 2012, 12, 21.	1.3	96
27	Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community. <i>PLoS ONE</i> , 2012, 7, e34156.	1.1	182
28	Virological Breakthrough: A Risk Factor for Loss to Followup in a Large Community-Based Cohort on Antiretroviral Therapy. <i>AIDS Research and Treatment</i> , 2011, 2011, 1-6.	0.3	15
29	Burden of New and Recurrent Tuberculosis in a Major South African City Stratified by Age and HIV-Status. <i>PLoS ONE</i> , 2011, 6, e25098.	1.1	87
30	Time to Initiation of Antiretroviral Therapy Among Patients With HIV-Associated Tuberculosis in Cape Town, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 136-140.	0.9	34
31	Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. <i>BMC Infectious Diseases</i> , 2011, 11, 258.	1.3	41
32	Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e1-e8.	0.9	115
33	Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. <i>BMC Infectious Diseases</i> , 2010, 10, 329.	1.3	17
34	Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. <i>South African Medical Journal</i> , 2010, 100, 827.	0.2	27
35	Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. <i>Aids</i> , 2009, 23, 335-342.	1.0	112
36	The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. <i>Tropical Medicine and International Health</i> , 2009, 14, 722-731.	1.0	113

#	ARTICLE	IF	CITATIONS
37	Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. <i>Aids</i> , 2008, 22, 1679-1681.	1.0	92
38	Promoting Retention in Care: An Effective Model in an Antiretroviral Treatment Service in South Africa. <i>Clinical Infectious Diseases</i> , 2007, 45, 803-803.	2.9	13
39	Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. <i>Antiviral Therapy</i> , 2007, 12, 83-8.	0.6	101
40	Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. <i>Antiviral Therapy</i> , 2007, 12, 753-60.	0.6	67
41	Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort. <i>Antiviral Therapy</i> , 2007, 12, 753-760.	0.6	115